Paediatric Exercise and Cardiac Performance Study

• Conditions: Cardiac performance in high school adolescents; Cardiovascular - Normal development and function of the cardiovascular system

• Registration Number: ACTRN12606000470594
• Lead Sponsor: Gary J Browne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-11-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

High school adolescents, both males and females, aged between 12 and 16 years who are physically fit and are free of known illnesses or diseases that may affect their exercise ability. Due to the fact that the study is specifically aiming to develop hydration strategies for elite and even professional sports players and young people who usually involve in high intensity exercise, ordinary adolescents are not considered as the target population. Potential subjects will be recruited only from regional high schools that are designated as centres of excellence for Sports, hence, the inclusion criteria are the high school students aged between 12 and 16 years who are attending one of the regional Sports High School within the catchment areas of he Sydney West Area Health Services.

Exclusion Criteria

Students who are diagnosed with any chronic illnesses and diseases that may affect their exercise ability and students who are diagnosed as over weight and obese will not be included in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The main outcomes of the study are the cardiac function measurements using the change of stroke volume SV (mL/beat) as the primary indicator. Fifteen minutes prior to the retesting exercise session, subjects in the treatment group will be pre-loaded with oral fluid. The difference between the baseline and retesting measures will be calculated as the change in SV. All cardiac function measurements will be made through a transcutaneous approach using the Ultrasonic Cardiac Output Monitor (USCOM) using a 3.3 hertz transducer.[The stroke volume will be assessed at the single baseline exercise session, as well as the single retesting exercise session. At each session the SV will be measured at the following timepoints: 1) at a resting stage immediately before the exercise; 2) at a significant exercise stage (30% VO2max); 3) at a sub-maximal stage (50% VO2max); 4) at a maximal exercise stage (75%VO2max); 5) at the point of exhaustion; and 6) 3 minutes post exercise.]

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes include cardiac output (L/min), Cardiac Index (L/min/m2).[These outcomes will be assessed at the single baseline exercise session, as well as the single retesting exercise session. At each session these outcomes will be measured at the following timepoints: 1) at a resting stage immediately before the exercise; 2) at a significant exercise stage (30% VO2max); 3) at a sub-maximal stage (50% VO2max); 4) at a maximal exercise stage (75%VO2max); 5) at the point of exhaustion; and 6) 3 minutes post exercise. Fifteen minutes prior to the retesting exercise session, subjects in the treatment group will be pre-loaded with oral fluid. The difference between the baseline and retesting measures will be calculated as the change in SV. All cardiac function measurements will be made through a transcutaneous approach using the Ultrasonic Cardiac Output Monitor (USCOM) using a 3.3 hertz transducer.]